Similar articles

• Frequency, predictors, and consequences of maintenance infliximab therapy intensification in ulcerative colitis.

  Fernández-Salazar L, Barrio J, Muñoz F, Muñoz C, Pajares R, Rivero M, Prieto V, Legido J, Bouhmidi A, Herranz M, González-Redondo G, Fernández N, Santos F, Sánchez-Ocaña R, Joao D; ACAD (Asociación Castellana de Aparato Digestivo) Researchers. Fernández-Salazar L, et al. Rev Esp Enferm Dig. 2015 Sep;107(9):527-33. Rev Esp Enferm Dig. 2015. PMID: 26334458
• Infliximab Efficacy and Safety in an Ulcerative Colitis Patient with Systemic Lupus Erythematosus.

  Ben-Horin S, Ungar B, Eliakim R, Langevitz P. Ben-Horin S, et al. J Crohns Colitis. 2016 Jun;10(6):752-3. doi: 10.1093/ecco-jcc/jjw034. Epub 2016 Jan 30. J Crohns Colitis. 2016. PMID: 26826571 No abstract available.
• Immune thrombocytopenia in ulcerative colitis.

  Casella G, Antonelli E, Villanacci V, Salemme M, Di Bella C, Baldini V, Bassotti G. Casella G, et al. Tech Coloproctol. 2016 Jul;20(7):499-500. doi: 10.1007/s10151-016-1471-1. Epub 2016 Apr 30. Tech Coloproctol. 2016. PMID: 27137208 No abstract available.
• Golimumab for moderately to severely active ulcerative colitis.

  Kedia S, Ahuja V, Makharia GK. Kedia S, et al. Expert Rev Clin Pharmacol. 2016 Oct;9(10):1273-82. doi: 10.1080/17512433.2016.1221759. Epub 2016 Aug 18. Expert Rev Clin Pharmacol. 2016. PMID: 27498886 Review.
• A review of infliximab use in ulcerative colitis.

  Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB. Wilhelm SM, et al. Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014. Clin Ther. 2008. PMID: 18343261 Review.